Innovation for Cellular Therapies: Pipeline of novel immunomodulating molecules delivering unrivaled enhancement for cancer targeting T-cells and NK-cells. Vycellix is a startup biotech company, advancing its proprietary pipeline of novel immunomodulators as therapeutics for cancers and infectious disease, as well as establishing these products as platform technology for the efficient, cost-effective modulation of cell and gene therapies.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
Vycellixs pre-IND product pipeline includes the novel molecules VY-OZ and VY-X, which have demonstrated unrivaled enhancement of T-cells and natural killer cells (NKcells). These products have shown to be capable of: delivering optimal and costeffective gene modification; rapidly increasing in vivo and ex vivo immune response, and; yielding unprecedented amplification of killing capacity for cytotoxic lymphocytes.